PYC Therapeutics (ASX:PYC) has taken a significant step forward in its goal to deliver the first treatment for Autosomal Dominant Optic Atrophy, announcing the initiation of a global repeat-dose Phase 1b clinical study of its investigational RNA therapy, PYC-001.
PYC Therapeutics launches global repeat-dose trial for potential first-in-class ADOA treatment
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
Canberra discovers what it really feels like to face a single buyer, and the response is hypocrisy
November 17, 2026 - - Latest News -
US biotech lobby's call for a White House strategy echoes AusBiotech push
November 17, 2026 - - Latest News -
Third global honour of 2026 for cochlear implant pioneer Graeme Clark
November 17, 2026 - -
Ipsen marks 25 years in Australia as rare disease listings broaden patient access
November 17, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 -

